Hematology

Latest News

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

A rare case report describes a young woman whose relapse of AML following MPN coincided with severe worsening of pulmonary hypertension, highlighting the need for vigilant cardiopulmonary monitoring in hematologic malignancies.

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

The analysis combined data from 3 major CLL clinical trials—ELEVATE-TN, ELEVATE-RR, and ASCEND—and postmarketing surveillance from a global database. | Image credit: laszlo - stock.adobe.com
Acalabrutinib Shows Low Cardiac Toxicity in Clinical, Real-World Data

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits
May 2nd 2018

What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits

AJMC Staff
The chimeric antigen receptor T-cell therapy tisagenlecleucel has been approved for a second type of blood cancer; the National Institutes of Health has started recruiting individuals for a database that will include data on more than 1 million people; Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility.
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 1st 2018

Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education

Chimeric antigen receptor (CAR) T-cell treatments are still new enough that there are still unknown regarding long-term side effects, which is something patients need to understand before they undergo treatment, said Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Researchers Identify New Gene That Predisposes People to ALL
April 30th 2018

Researchers Identify New Gene That Predisposes People to ALL

Laura Joszt, MA
Researchers have identified a new gene that may predispose individuals to develop acute lymphoblastic leukemia (ALL). In addition, variants in the gene can influence patient response to treatment.
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26th 2018

Hemophilia: Treatment Landscape, Costs, and Disease Management

Jaime Rosenberg
At the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting, experts addressed the cost of treating patients with hemophilia and the importance of care coordination to ensure a more holistic approach toward caring for these patients.
New Test Could Make Multiple Myeloma Diagnosis as Easy as Drawing a Blood Sample
April 23rd 2018

New Test Could Make Multiple Myeloma Diagnosis as Easy as Drawing a Blood Sample

Laura Joszt, MA
A new blood test could negate the need for bone biopsies to diagnose a variety of cancers, including multiple myeloma. The test uses a small, low-cost plastic chip that delivers the same diagnostic information of a biopsy through a simple blood draw.
Novel Drug Shows Promise in Acute Myeloid Leukemia by Suppressing Two Proteins
April 19th 2018

Novel Drug Shows Promise in Acute Myeloid Leukemia by Suppressing Two Proteins

Laura Joszt, MA
A novel drug that targets MDMX and MDM2, which inhibit a protein that suppresses tumors when they are overexpressed, has tripled the median survival rate in an animal model of human acute myeloid leukemia, according to new research.
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18th 2018

Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care

Thomas LeBlanc, MD, of the Duke Cancer Institute, addresses the importance of adding a palliative care specialist to the cancer care team.
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17th 2018

Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education

Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.
Identification of Genes Involved With MM Development Could Mean More Personalized Treatments
April 16th 2018

Identification of Genes Involved With MM Development Could Mean More Personalized Treatments

Laura Joszt, MA
The identification of 40 genes involved with the development of multiple myeloma could lead to the development of more personalized treatments.
Survivors of Childhood ALL Have Risk of Neurocognitive Issues Even Before Treatment
April 14th 2018

Survivors of Childhood ALL Have Risk of Neurocognitive Issues Even Before Treatment

Laura Joszt, MA
While increased risk of neurocognitive issues, such as long-term problems with attention, is common in survivors of childhood acute lymphoblastic leukemia (ALL), the risk may actually begin before treatment, according to a study published in JAMA Oncology.
Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma
April 14th 2018

Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma

Jaime Rosenberg
Researchers have identified genetic subtypes of diffuse large B-cell lymphoma that revise the molecular classification of the disease and could provide insight into why some patients respond to treatment and others don’t.
Pediatric Sickle Cell Disease Drug Gains European Orphan Designation
April 8th 2018

Pediatric Sickle Cell Disease Drug Gains European Orphan Designation

Kelly Davio
Sancilio Pharmaceuticals announced that it has received the European Medicines Agency’s Orphan Designation for its SC411 (which it plans to market as Altemia), a proposed treatment for sickle cell disease in pediatric patients, in the European Union. The FDA granted the proposed drug a similar designation—the Rare Pediatric Disease designation—in 2017.
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 7th 2018

Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma

While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
Screening for Multiple Myeloma Precursor Can Reduce Mortality and Slow Progression
April 5th 2018

Screening for Multiple Myeloma Precursor Can Reduce Mortality and Slow Progression

Laura Joszt, MA
Researchers have been trying to find a way to screen populations at high risk of developing a precursor condition to multiple myeloma in order to intervene early and reduce disease prevalence and mortality.
Site Logo
March 27th 2018

Pricing of CAR T Therapies Currently Aligns With Benefit, but Future Changes May Be Needed

Laura Joszt, MA
Despite price tags well over $350,000 for treatment, tisagenlecleucel, approved for children with B-cell acute lymphoblastic leukemia, and axicabtagene ciloleucel, approved for adults with certain B-cell subtypes of non-Hodgkin lymphoma, are considered cost effective, according to a report from the Institute for Clinical and Economic Review.
Site Logo
March 23rd 2018

In Updated Treatment Guidelines for MM, Supportive Care Still Plays a Key Role

Kelly Davio
“Even though we have all these fancy, effective drugs,” said Shaji K. Kumar, MD, “supportive care still plays an important role in multiple myeloma.”
Malignant Cells Can Predict Relapse After Treatment in Children With ALL
March 22nd 2018

Malignant Cells Can Predict Relapse After Treatment in Children With ALL

Laura Joszt, MA
Researchers have identified malignant cells that, if present, can predict whether a patient with acute lymphoblastic leukemia (ALL) will relapse after treatment.
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21st 2018

Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer

Thomas LeBlanc, MD, Duke Cancer Institute, addresses the ways palliative care and hospice can improve end-of-life outcomes for patients with blood cancers.
FDA Approves Brentuximab Vedotin for Frontline Treatment of Classical Hodgkin Lymphoma
March 21st 2018

FDA Approves Brentuximab Vedotin for Frontline Treatment of Classical Hodgkin Lymphoma

Jaime Rosenberg
The FDA has approved brentuximab vedotin (Adcentris) in combination with chemotherapy for adults with previously untreated state 3 or 4 classical Hodgkin lymphoma based on results of the ECHELON-1 study.
Patients With AML Have Significantly Lower Early Mortality at NCI-Designated Cancer Centers
March 17th 2018

Patients With AML Have Significantly Lower Early Mortality at NCI-Designated Cancer Centers

Laura Joszt, MA
Patients with acute myeloid leukemia (AML) who were treated at a National Cancer Institute-designated cancer center had a 53% lower risk of early mortality, according to a study published in Cancer.
NCI Researchers Find Drug May Prevent Resistance in Toxin-Based Leukemia Treatment
March 15th 2018

NCI Researchers Find Drug May Prevent Resistance in Toxin-Based Leukemia Treatment

Samantha DiGrande
A new study recently published in Proceedings of the National Academy of Sciences has identified a possible solution for improving the efficacy of moxetumomab pasudotox, or moxe, in patients with relapsed and chemotherapy-resistant acute lymphoblastic leukemia.
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10th 2018

Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care

Thomas LeBlanc, MD, Duke Cancer Institute, discusses the trends of hospice care services used among patients with blood cancer compared with patients with solid tumors.
Patients With Breast Cancer or Lymphoma Have Increased Risk of Heart Failure
March 10th 2018

Patients With Breast Cancer or Lymphoma Have Increased Risk of Heart Failure

Kaitlynn Ely
Patients who had breast cancer or lymphoma who were treated more than 3 times are more likely to develop congestive heart failure than those who did not have cancer, according to research being presented at the American College of Cardiology’s 67th Annual Scientific Session.
This Week in Managed Care: March 9, 2018
March 9th 2018

This Week in Managed Care: March 9, 2018

This week, the top managed care stories included Cigna's deal to buy Express Scripts; Seema Verma, Alex Azar, and Scott Gottlieb, MD, made the rounds at health conferences; an analysis finds FDA's accelerated approval pathway has been a success with hematology and oncology drugs.
Site Logo
March 8th 2018

Expedited Approval Is Successful for Cancer Therapies, FDA Says

Kelly Davio
Reviewing 25 years of experience with accelerated approvals (AAs) for malignant hematology and oncology drugs and biologics, FDA officials say that the AA program has demonstrated that it can be used successfully to expedite approval of safe, effective cancer therapies that balance uncertainty with the need to provide faster access to promising agents for serious and life-threatening diseases.
NIH Panel Features Experiences of Young Adults in Rare Disease Community
March 6th 2018

NIH Panel Features Experiences of Young Adults in Rare Disease Community

Kaitlynn Ely
During a discussion, 4 panelists addressed their main issues of growing up with rare diseases, including that physicians often doubted their feelings of pain and distress.
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
February 28th 2018

HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age

Laura Joszt, MA
New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Site Logo
February 28th 2018

The Importance of Teamwork in Oncology Care Transitions

Surabhi Dangi-Garimella, PhD
Coverage of patient-centered care updates from Patient-Centered Oncology Care, November 16-17, 2017.
Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment
February 25th 2018

Blood or Marrow Transplantation Recipients Experience Higher Risks of Cognitive Impairment

Kaitlynn Ely
Blood or marrow transplantation (BMT) can have an impact on a patient’s cognitive functioning, affecting a survivor’s ability to integrate with a group of people and return to work. In addition, BMT recipients can experience a weakened memory, a loss of attention and concentration, and difficulty learning.
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018

ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit

Jaime Rosenberg
CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
<1
...
19202122232425262728>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo